Congressional committee investigates former NCI Director Richard Klausner’s role in $40 million Harvard contract; NIH begins internal review. Klausner: investigation casts “strange innuendoes.” Text of committee’s letter.
Also in this 12-page issue: NCI gives Doroshow and Fine “lead role” in clinical trials system review.
NCI program announcement available, contract awards listed.
Trending Stories
- As daraxonrasib hits the clinic, Frank McCormick says RAS is bigger than pancreatic cancer
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Cancer leaders play “musical chairs” as executive jobs fill at top cancer centers
Lee replaces Pisters at MD Anderson, Tuveson moves to Duke, and Mitchell is named director at University of Florida - mRNA vaccine for melanoma is hailed as a turning point in medicine
The data from Moderna and Merck’s trial have yet to be presented









